Clinical Trials & Research Studies in Canada(Updated 8/25)

Smart About Meds (SAM) RCT

NCT05371548

Recruiting

Introduction: Almost half of patients discharged from hospital are re-admitted or return to the emergency department (ED) within 90 days. Patient nonadherence to medication changes during hospitalization and the use of potentially inappropriate medications (PIMs) both contribute to the risk of adverse events post-discharge. Smart About Meds (SAM) is a patient-centered mobile application designed to target medication nonadherence and PIMs use. This protocol describes a randomized controlled tria... Read More

Introduction: Almost half of patients discharged from hospital are re-admitted or return to the emergency department (ED) within 90 days. Patient nonadherence to medication changes during hospitalization and the use of potentially inappropriate medications (PIMs) both contribute to the risk of adverse events post-discharge. Smart About Meds (SAM) is a patient-centered mobile application designed to target medication nonadherence and PIMs use. This protocol describes a randomized controlled trial (RCT) to evaluate the effectiveness of SAM. Methods \& Analysis: A pragmatic, stratified RCT will be conducted among 3,250 patients discharged from internal medicine, cardiac care, cardiac surgery, vascular surgery, and respiratory units of the Royal Victoria Hospital and the Montreal General Hospital. At discharge, patients will be randomized 1:1 to usual care or the SAM intervention. SAM integrates novel user-centered features (e.g. continuously updated medication list with pill images, side-effect checker, interaction checker) with pharmacist monitoring to tackle post-discharge nonadherence to new medication regimens. SAM also notifies patients of PIMS in their regimen, with advice to discuss with their physician. Following discharge, patients will be followed for 90 days, during which the occurrence of the composite outcome of ED visits, hospital readmissions, or death will be measured. Secondary outcomes will include the individual components of the composite outcome, nonadherence to medication changes, defined as failure to fill a new prescription, filling a modified prescription at the incorrect dose, or filling discontinued medications, secondary medication adherence, patient empowerment, and health-related quality of life. An intention-to-treat analysis will evaluate the effectiveness of SAM. Multivariable logistic regression will estimate differences between treatment groups in the proportion of patients nonadherent to at least one medication change. With a sample size of 3,250, there will be 80% power to detect a 5% absolute reduction in this outcome. Two-way interaction terms will test hypothesized modifiers of SAM's effectiveness, including hospital, unit, age, sex, gender and comorbidity burden. Binary and continuous secondary outcomes will be assessed using multivariable logistic and linear regression, respectively. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/30/2024

Locations: McGill University Health Centre, Montreal, Quebec

Conditions: Medication Adherence

Register for Updates

Learn More ›

Fasting-mimicking Diet in Treatment of Depressive Symptoms in IBD

NCT05382897

Recruiting

Inflammatory bowel disease (IBD) is a chronic illness characterized by inflammation of the intestine. Many individuals with IBD suffer from depressive symptoms and anxiety which can lead to a decreased quality of life, poor treatment compliance, and higher morbidity and mortality. The object of this clinical trial is to investigate the effects of a fasting mimicking diet in IBD patients who are suffering with symptoms of depression. Participants will carry out 3 cycles of a 5-day period of a pla... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

08/30/2024

Locations: University of Alberta Hospital, Edmonton, Alberta +1 locations

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis

Register for Updates

Learn More ›

Real-World Effectiveness of Mavacamten in Canada

NCT06338202

Recruiting

The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/30/2024

Locations: London Health Science Centre (LHSC), London, Ontario

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Register for Updates

Learn More ›

Study Looking at Biomarkers in Ovarian Cancer

NCT03419689

Recruiting

This is a sample study that will collect biological samples (blood, tumor tissue, ascites, and/or other fluids) from gynecological cancer patients for biomarker research. In addition, the results of the testing done on the samples will be given to the participant's treating physician who may use the information to guide treatment decisions.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

08/28/2024

Locations: Royal Victoria Regional Health Centre, Barrie, Ontario +6 locations

Conditions: Gynecologic Cancer

Register for Updates

Learn More ›

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921

Recruiting

Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-thre... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

08/27/2024

Locations: Cedars-Sinai Comprehensive Transplant Center, Los Angeles, California +105 locations

Cedars-Sinai Comprehensive Transplant Center, Los Angeles, California

University of Colorado, Aurora, Colorado

Tampa General Hospital, Tampa, Florida

Piedmont Healthcare, Atlanta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

The University of Chicago Medicine, Chicago, Illinois

University of Maryland School of Medicine, Baltimore, Maryland

Weill Cornell Medicine, New York, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Montefiore Medical Center, New York, New York

University of Cincinnati, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

University of Pennsylvania, Philadelphia, Pennsylvania

Vanderbilt University Medical Center, Nashville, Tennessee

Baylor College of Medicine (Scott & White), Dallas, Texas

Michael E DeBakey VA Medical Center, Houston, Texas

Baylor St. Luke's Medical Centre, Houston, Texas

University of Utah Health, Salt Lake City, Utah

Austral University Hospital, Buenos Aires, Not set

Hospital Alemán, Buenos Aires, Not set

Italian Hospital in Buenos Aires, Buenos Aires, Not set

Austin Hospital, Heidelberg, Not set

Sir Charles Gairdner Hospital, Nedlands, Not set

Royal Prince Alfred Hospital, Sydney, Not set

Medical University of Vienna, Department of Transplant Surgery, Wien, Not set

CUB Erasme Hospital, Brussels, Not set

Ghent University Hospital, Ghent, Not set

UZ Leuven, Leuven, Not set

Walter Cantídio University Hospital, Fortaleza, Not set

Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Not set

Hospital das Clínicas da Universidade de São Paulo, São Paulo, Not set

University of Alberta, Edmonton, Not set

University of Toronto, Multiorgan Transplant Program, Toronto, Not set

Pablo Tobón Uribe Hospital, Medellín, Not set

Institute for Clinical and Experimental Medicine, Praha, Not set

APHP Beaujon, Clichy, Not set

APHP Henri Mondor, Créteil, Not set

Hôpital de la Croix-Rousse, Lyon, Not set

CHU Montpellier-Hôpital Saint Eloi, Montpellier, Not set

APHP Hôpitaux Universitaires Pitié Salpêtrière, Paris, Not set

CHU Rennes, Hôpital De Pontchaillou, Rennes, Not set

Hautepièrre Hospital, Service de Réanimation Médicale, Strasbourg, Not set

Trousseau Hospital,, Tours, Not set

Hôpital Paul Brousse, Villejuif, Not set

University Hospital Regensburg, Regensburg, Eastern Bavaria

Universitätsklinikum Schleswig-Holstein (UKSH), Kiel, Schleswig-Holstein

University Hospital Aachen, Aachen, Not set

Charité University Hospital, Berlin, Not set

Goethe University Clinic, Frankfurt, Not set

University Medical Center, Hamburg Eppendorf, Hamburg, Not set

Hannover Medical School, Hannover, Not set

University Hospital Heidelberg, Heidelberg, Not set

Jena University Hospital, Jena, Not set

Universitätsklinikum Schleswig-Holstein (UKSH), Kiel, Not set

Leipzig University Hospital, Leipzig, Not set

University Hospital Mainz, Mainz, Not set

LMU Großhadern, Munich, Not set

UKM Muenster, Münster, Not set

University Hospital Tübingen, Tübingen, Not set

Queen Mary Hospital, The University of Hong Kong, Hong Kong, Not set

Indraprastha Apollo Hospitals, New Delhi, Delhi

Aster CMI Hospital, Bengaluru, Karnataka

Kasturba Hospital, Mumbai, Maharashtra

Seth GSMC & KEM Hospital, Mumbai, Maharashtra

Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan

Dr.Rela Institute & Medical Centre, Chennai, Not set

Fortis Hospital Noida, FEHI, FMRI, Gurugramam, Not set

Medanta Medicity, Gurugramam, Not set

Amrita Institute of Medical Sciences, Kochi, Not set

Global Hospital. Super speciality & transplant centre, Mumbai, Not set

Max Saket Hospital, New Delhi, Not set

Yashoda Hospitals, Secunderabad, Not set

Ospedale Papa Giovanni XXIII-, Bergamo, Not set

S.Orsola Hospital - Alma Mater Studiorum University of Bologna, Bologna, Not set

Ca' Granda. Policlinico Milano, Milan, Not set

Niguarda Hospital, Milan, Not set

University and Hospital of Padova, Padova, Not set

Kyushu University Hospital, Fukuoka, Not set

Hiroshima University Hospital, Hiroshima, Not set

Kyoto University Hospital, Kyoto, Not set

Nagasaki University Hospital, Nagasaki, Not set

Tokyo University Hospital, Tokyo, Not set

Samsung Medical Center, Seoul, Not set

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Not set

University Medical Center Groningen (UMCG), Groningen, Not set

Erasmus MC University Medical Center, Rotterdam, Not set

Auckland City Hospital- New Zealand Liver Transplant Unit, Auckland, Not set

Medical University of Warsaw, Dept. of General, Transplant & Liver Surgery, Warsaw, Not set

Hospital Curry Cabral, Lisboa, Not set

Hospital Clinic in Barcelona, Barcelona, Not set

Hospital Vall d'Hebron, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital Marqués de Valdecilla, Santander, Not set

Hospital Universitario Virgen del Rocío, Sevilla, Not set

Hospital Universitari i Politècnic La Fe, Valencia, Not set

Karolinska Institutet, Stockholm, Not set

Geneva University Hospital (HUG), Geneva, Not set

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set

Inonu University, Liver Transplantation Institute, Malatya, Anatolia

Istanbul Memorial Bahcelievler Hospital, Istanbul, Not set

Queen Elizabeth Hospital Birmingham, Birmingham, Not set

Scottish Liver Transplant Unit, Royal Infirmary, Edinburgh, Not set

Leeds Teaching Hospitals NHS Trust, Leeds, Not set

King's College Hospital, London, Not set

Royal Free Hospital, London, Not set

Conditions: Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

Register for Updates

Learn More ›

Functional Evolution of Traumatic Brain Injured Adults During Rehabilitation and Social Participation

NCT05022940

Recruiting

The research project aims to better understand the multiple factors related to the clinical evolution and the social participation of traumatic brain injured (TBI). The project will provide better understanding of the patients' evolution during rehabilitation after TBI in terms of adaptation and social participation, assess the effect of rehabilitation and study social participation outcomes and quality of life of TBI patients one-year post-rehabilitation. Project benefits include improvement of... Read More

Gender:

ALL

Ages:

17 years and above

Trial Updated:

08/27/2024

Locations: CRIR, Montreal, Quebec

Conditions: Traumatic Brain Injury

Register for Updates

Learn More ›

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

NCT05870748

Recruiting

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

08/27/2024

Locations: Arizona Oncology Associates, PC-Hope, Tucson, Arizona +38 locations

Arizona Oncology Associates, PC-Hope, Tucson, Arizona

Sutter Health, Daly City, California

MedStar Washington Hospital Center, Washington, District of Columbia

Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida

USF Research & Innovation, Tampa, Florida

Sinai Hospital of Baltimore, Baltimore, Maryland

University of Massachusetts Chan Medical School, Worcester, Massachusetts

Minnesota Oncology Hematology, Minneapolis, Minnesota

Nebraska Methodist Hospital, Omaha, Nebraska

Optimum Clinical Research Group, Albuquerque, New Mexico

NYU Langone Health, New York, New York

Good Samaritan Hospital Medical Center, West Islip, New York

University of Cincinnati Medical Center, Cincinnati, Ohio

Ohio State University Center, Columbus, Ohio

Kettering Health, Kettering, Ohio

Oklahoma Cancer Specialists and Research Institute- Tulsa Cancer Center, Tulsa, Oklahoma

Oncology Associates of Oregon, PC, Eugene, Oregon

Providence Gynecologic Oncology Clinic, Portland, Oregon

Lancaster General Hospital, Lancaster, Pennsylvania

Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Texas Oncology, Dallas, Texas

Texas Oncology-DFW, Dallas, Texas

Texas Oncology-San Antonio, San Antonio, Texas

Texas Oncology - The Woodlands, The Woodlands, Texas

Virginia Cancer Specialists, Fairfax, Virginia

Chris O'Brien Lifehouse, Camperdown, New South Wales

Prince of Wales Hospital, Randwick, New South Wales

Westmead Hospital, Westmead, New South Wales

McGill University Health Centere (MUHC)-Glen Site, Montréal, Quebec

Princess Margaret Cancer Center, Toronto, Not set

Sheba Medical Center, Ramat Gan, Not set

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do

Keimyung University Dongsan Hospital, Daegu, Not set

National Cancer Center, Gyeonggi-do, Not set

Gachon University Gil Hospital, Incheon, Not set

Yonsei University, Severance Hospital, Seoul, Not set

Health New Zealand - Te Whatu Ora Capital, Coast, and Hutt Valley - Wellington Regional Hospital, Newtown, Wellington

Curie Centre, Oncology centre, Novena, Not set

National Cancer Center Singapore, Singapore, Not set

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer

Register for Updates

Learn More ›

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

NCT06485076

Recruiting

Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in goals of care conversations occurring late in the illness trajectory and aggressive care being received in the last 30 days of life. Early palliative care alongside usual cancer care has been shown to improve patient outcomes such as symptom burden, mood, and quality of lif... Read More

Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in goals of care conversations occurring late in the illness trajectory and aggressive care being received in the last 30 days of life. Early palliative care alongside usual cancer care has been shown to improve patient outcomes such as symptom burden, mood, and quality of life in patients with solid tumours (e.g. lung, breast or gynecological cancers), but has not been explored among patients with blood cancers to date. The goal of this clinical trial is to a brief early palliative care intervention for patients with multiple myeloma and aggressive B cell lymphoma attending the Princess Margaret Cancer Centre. The main goals of the study are: * To see if it is possible to apply the early palliative care intervention for patients with multiple myeloma and aggressive lymphoma * To see if this early palliative care intervention works well for these patients * To compare patient experiences with early palliative care and usual care. Participants will be randomly assigned to one of two groups: one group will receive early palliative care in addition to usual care from their blood cancer doctor, and the other group will receive usual care from their blood cancer doctor only. All participants will be asked to fill out questionnaires about their symptom burden, mood, quality of life, and satisfaction with care throughout the study. Some participants will also be asked to take part in interviews at the end of the trial to answer questions about their experience taking part in the study. Researchers will compare the results between the two groups to see if there are any improvements in quality of life for the patients who received early palliative care. The researchers will use the results of this study to guide in the development of a larger clinical trial. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/27/2024

Locations: Princess Margaret Cancer Centre, Toronto, Not set

Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma Stage III, Multiple Myeloma Progression, Multiple Myeloma, B Cell Lymphoma, Lymphoma, B-Cell, Aggressive Lymphoma

Register for Updates

Learn More ›

Myeloproliferative Neoplasms (MPNs) Patient Registry

NCT02760238

Recruiting

The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.

Gender:

ALL

Ages:

All

Trial Updated:

08/26/2024

Locations: Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Mastocytosis, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myelomonocytic, Juvenile, Chronic Eosinophilic Leukemia-not Otherwise Specified, Myelodysplastic-Myeloproliferative Diseases, Neoplasms, Leukemia, Myelomonocytic, Chronic

Register for Updates

Learn More ›

Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism

NCT03249012

Recruiting

This study aims to compare two different protocols commonly used in the management of post thyroidectomy hypoparathyroidism : PTH based calcium repletion and empiric repletion. The investigators aim to compare the quality of life associated with these two protocols in a randomized trial.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/26/2024

Locations: CHU de Quebec, Québec, Quebec

Conditions: Hypoparathyroidism Postprocedural, Quality of Life

Register for Updates

Learn More ›

PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation

NCT04901884

Recruiting

Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA. PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH). Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent r... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/26/2024

Locations: University Health Network, Toronto, Ontario

Conditions: Pulmonary Hypertension

Register for Updates

Learn More ›

To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA

NCT06436911

Recruiting

Currently, several vaccines are available to combat the COVID-19 pandemic. The persistence of SARS-CoV-2 globally requires the development of additional vaccines to aid in preventing further SARS-CoV-2 infections. Covigenix VAX-002 is a vaccine based off its predecessors VAX-001 and VAX-001-1b. All three are plasmid DNA vaccines that express key antigenic determinants from SARS-CoV-2 and use the Entos Pharmaceuticals' Fusogenix proteo-lipid vehicle (PLV) platform. Currently, the safety and toler... Read More

Currently, several vaccines are available to combat the COVID-19 pandemic. The persistence of SARS-CoV-2 globally requires the development of additional vaccines to aid in preventing further SARS-CoV-2 infections. Covigenix VAX-002 is a vaccine based off its predecessors VAX-001 and VAX-001-1b. All three are plasmid DNA vaccines that express key antigenic determinants from SARS-CoV-2 and use the Entos Pharmaceuticals' Fusogenix proteo-lipid vehicle (PLV) platform. Currently, the safety and tolerability of VAX-001 and VAX-001-1b for primary vaccination following 1 or 2 doses are being investigated in a Phase 1/2 study (ENTVAX01-101). In Phase 1, VAX-001 was administered to healthy adults on Day 0 and Day 14, as either 2 low doses (100 μg/dose) or 2 high doses (250 μg/dose). Overall, data suggest that VAX-001 is safe at both the low and high dose levels. The Phase 2 part evaluates VAX-001-1b in adults at a 100 μg dose level on a 1-dose and a 2-dose schedule (Days 0 and 28). An interim analysis conducted on data from 18 participants in the sentinel group who had received their first dose of 100 μg showed that VAX-001-1b was overall safe with minor adverse events (AEs) registered. No serious adverse events (SAEs) were reported. After a review of the data, the Data Safety Monitoring Committee (DSMC) provided their recommendations for the participants in the 100 μg dose sentinel group to receive a second dose. The present study investigates the safety and immunogenicity of VAX-002 when given as a booster dose to generally healthy adults aged 18 years or older who have received a primary vaccination course or a booster dose of an authorized COVID-19 vaccine at least 3 months prior to Day 0. VAX-002 was specifically designed to address the new circulating omicron variants of SARS-CoV-2. The study consists of 2 parts: a dose-finding/safety evaluation part (Phase 1) to determine the dose of VAX-002 for booster vaccination (100 μg or 250 μg) followed by an adaptive Phase Read Less

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

08/26/2024

Locations: University of Alberta, Edmonton, Alberta +5 locations

Conditions: COVID-19

Register for Updates

Learn More ›

All Clinical Trials in Canada

Match to Clinical Trials